The double blind randomized comparative study of MRQ-01 in the cancer patients with breakthrough pain.
Phase 3
- Conditions
- Cancer-related breakthrough pain
- Registration Number
- JPRN-jRCT2080222864
- Lead Sponsor
- Maruishi Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 84
Inclusion Criteria
The cancer-related breakthrough pain which rescue needs
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method